Acceleron Pharma Inc Revenue Growth Rates (XLRN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Acceleron Pharma inc  (NASDAQ: XLRN)
 

XLRN's Revenue Growth by Quarter and Year

Acceleron Pharma Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

XLRN Revenue (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
4th Quarter December -
3rd Quarter September 34.20
2nd Quarter June 27.94
1st Quarter March 24.76
FY 86.90

XLRNs Annual Revenue
Acceleron Pharma Inc's Revenue in the fiscal year 2020 $ 92.52 millions
Acceleron Pharma Inc's Revenue in the fiscal year 2019 $ 73.99 millions
Acceleron Pharma Inc's Revenue in the fiscal year 2018 $ 13.99 millions
Acceleron Pharma Inc's Revenue in the fiscal year 2017 $ 13.48 millions
Acceleron Pharma Inc's Revenue in the fiscal year 2016 $ 27.77 millions




XLRN Revenue third quarter 2021 Y/Y Growth Comment
Acceleron Pharma inc reported Revenue rise of 51.59% year on year in the third quarter 2021, to $ 34.20 millions, this is lower than Acceleron Pharma Inc's recent average Revenue rise of 95.02%.

Looking into third quarter 2021 results within Biotechnology & Pharmaceuticals industry 41 other companies have achieved higher Revenue growth. While Acceleron Pharma Inc' s Revenue jump of 51.59% ranks overall at the positon no. 746 in the third quarter 2021.


XLRN Revenue ( Y/Y Growth %) 2021
 2020 2019 2018
4th Quarter December - -34.24 % 929.84 % 2.96 %
3rd Quarter September 51.59 % 435.87 % 29.14 % 8.31 %
2nd Quarter June -29.71 % 43.66 % 649.86 % 20.59 %
1st Quarter March 470.51 % 56.12 % -13.93 % -12.94 %
FY   - 25.03 % 428.57 % -

Financial Statements
Acceleron Pharma Inc's third quarter 2021 Revenue $ 34.20 millions XLRN's Income Statement
Acceleron Pharma Inc's third quarter 2020 Revenue $ 22.56 millions Quarterly XLRN's Income Statement


XLRN Revenue (Quarter on Quarter Growth %)

 2021
 2020 2019 2018
4th Quarter December - 14.67 % 834.44 % 17.18 %
3rd Quarter September 22.4 % -43.25 % -84.78 % -11.65 %
2nd Quarter June 12.84 % 815.9 % 895.32 % 14.24 %
1st Quarter March -4.29 % -88.97 % -27.23 % -12.94 %
FY (Year on Year)   - 25.03 % 428.57 % -


Back to XLRN Growth rate Comparisons >> Back to XLRN Growth rate Comparisons >>


Revenue third quarter 2021 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #42
Healthcare Sector #132
Overall #746

Revenue Y/Y Growth Statistics
High Average Low
930.9 % 95.02 % -84.74 %
(Dec 31 2019)   (Dec 31 2014)
Revenue third quarter 2021 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #42
Healthcare Sector #132
Overall #746
Revenue Y/Y Growth Statistics
High Average Low
930.9 % 95.02 % -84.74 %
(Dec 31 2019)   (Dec 31 2014)

Revenue by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Acceleron Pharma Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
895.18 % 96.39 % -88.96 %
(Jun 30 2019)  


XLRN's III. Quarter Q/Q Revenue Comment
Acceleron Pharma inc achieved in the III. Quarter 2021 below company average Revenue jump of 22.4% quarter on quarter, to $ 34.20 millions.

Although the III. Quarter 2021 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the -43.25% growth in the III. Quarter a year ago

Within Biotechnology & Pharmaceuticals industry 18 other companies have achieved higher Revenue quarter on quarter growth. While Acceleron Pharma Inc's Revenue growth quarter on quarter, overall rank is 614.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #19
Healthcare Sector #128
Overall #614
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #19
Healthcare Sector #128
Overall #614
Revenue Q/Q Growth Statistics
High Average Low
895.18 % 96.39 % -88.96 %
(Jun 30 2019)  


XLRN's III. Quarter Q/Q Revenue Comment
Acceleron Pharma inc achieved in the III. Quarter 2021 below company average Revenue jump of 22.4% quarter on quarter, to $ 34.20 millions.

III. Quarter 2021 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -43.25% in the III. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 18 other companies have achieved higher Revenue quarter on quarter growth. While Acceleron Pharma Inc's Revenue growth quarter on quarter, overall rank is 614.


Acceleron Pharma Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2021)		 12 Months Ending
(Jun 30 2021)		 12 Months Ending
(Mar 31 2021)		 12 Months Ending
(Dec 31 2020)		 12 Months Ending
(Sep 30 2020)
Cumulative Revenue 12 Months Ending $ 112.76 $ 101.13 $ 112.94 $ 92.52 $ 106.00
Y / Y Revenue Growth (TTM) 6.38 % 15.38 % 49.47 % 25.04 % 175.53 %
Year on Year Revenue Growth Overall Ranking # 193 # 868 # 167 # 266 # 190
Seqeuential Revenue Change (TTM) 11.51 % -10.46 % 22.06 % -12.71 % 20.94 %
Seq. Revenue Growth (TTM) Overall Ranking # 1379 # 2220 # 104 # 1899 # 2660


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2021 period, Acceleron Pharma Inc's cumulative twelve months Revenue were $ 113 millions, company would post below average annual Revenue growth of 20.94% year on year, if the fiscal year would end at Sep 30 2021.
A slow-down in the Acceleron Pharma Inc's Revenue growth from the 27.94% growth in Jun 30 2021.

In the Healthcare sector 57 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 193, from total ranking in previous quarter at 868.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 35
Healthcare Sector # 58
Overall # 193

Revenue TTM Y/Y Growth Statistics
High Average Low
458.07 %
 69.6 %
-58.36 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 35
Sector # 240
S&P 500 # 1379
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2021 period, Acceleron Pharma Inc's cumulative twelve months Revenue were $ 113 millions, company would post below average annual Revenue growth of -58.36% year on year, if the fiscal year would end at Sep 30 2021.
A slow-down in the Acceleron Pharma Inc's Revenue growth from the 27.94% growth in Jun 30 2021.

In the Healthcare sector 57 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 193, from total ranking in previous quarter at 868.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 35
Healthcare Sector # 58
Overall # 193

Revenue TTM Y/Y Growth Statistics
High Average Low
458.07 %
69.6 %
-58.36 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 35
Sector # 240
S&P 500 # 1379




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
XLRN's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2021 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2021
Viewray Inc 90.13%$ 90.135 millions
Repligen Corp89.47%$ 89.471 millions
Sanuwave Health Inc 89.38%$ 89.385 millions
Inari Medical Inc 88.34%$ 88.340 millions
Fate Therapeutics Inc 88.21%$ 88.211 millions
Pacific Biosciences Of California Inc 83.47%$ 83.471 millions
Cyclo Therapeutics Inc 81.57%$ 81.567 millions
Teladoc Health Inc 80.62%$ 80.622 millions
Scholar Rock Holding Corp79.91%$ 79.914 millions
Hims and Hers Health Inc 79.49%$ 79.491 millions
Opiant Pharmaceuticals Inc 79.43%$ 79.430 millions
Paratek Pharmaceuticals Inc 78.98%$ 78.981 millions
Oak Street Health Inc 78.39%$ 78.388 millions
Halozyme Therapeutics Inc 77.34%$ 77.338 millions
Harmony Biosciences Holdings inc 77.01%$ 77.009 millions
Karyopharm Therapeutics Inc 76.67%$ 76.670 millions
Elicio Therapeutics Inc 76.54%$ 76.542 millions
Soc Telemed Inc 76.34%$ 76.342 millions
10x Genomics Inc 74.47%$ 74.467 millions
Zynex inc 73.70%$ 73.704 millions
Inspire Medical Systems inc 72.10%$ 72.103 millions
Albireo Pharma inc 71.94%$ 71.938 millions
Akumin Inc 71.13%$ 71.131 millions
Lifestance Health Group Inc 70.46%$ 70.457 millions
Apyx Medical Corp70.13%$ 70.132 millions
Milestone Scientific Inc 69.19%$ 69.185 millions
Xoma Royalty Corporation68.76%$ 68.761 millions
Absci Corp68.01%$ 68.013 millions
Invitae Corporation66.45%$ 66.446 millions
Dyadic International Inc 66.43%$ 66.425 millions


About Acceleron Pharma Inc Revenue Growth Rates (XLRN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.